4.46
+0.11(+2.53%)
Currency In USD
| Previous Close | 4.35 |
| Open | 4.33 |
| Day High | 4.71 |
| Day Low | 4.28 |
| 52-Week High | 6.19 |
| 52-Week Low | 2.22 |
| Volume | 1.26M |
| Average Volume | 1.29M |
| Market Cap | 387.19M |
| PE | -3.84 |
| EPS | -1.16 |
| Moving Average 50 Days | 3.97 |
| Moving Average 200 Days | 4.42 |
| Change | 0.11 |
If you invested $1000 in Rezolute, Inc. (RZLT) 10 years ago, it would be worth $48.22 as of July 01, 2025 at a share price of $4.46. Whereas If you bought $1000 worth of Rezolute, Inc. (RZLT) shares 5 years ago, it would be worth $892 as of July 01, 2025 at a share price of $4.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
GlobeNewswire Inc.
May 28, 2025 12:00 PM GMT
Target enrollment exceeded with 62 participants enrolled, including approximately 15 percent from U.S. sites Topline data is anticipated in December of 2025 REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezo
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
GlobeNewswire Inc.
May 05, 2025 12:00 PM GMT
Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Re
Rezolute, Inc. Announces Closing of Underwritten Offering
GlobeNewswire Inc.
Apr 25, 2025 8:30 PM GMT
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the